PT - JOURNAL ARTICLE AU - Angela J. Yoon AU - Regina M. Santella AU - Shuang Wang AU - David I. Kutler AU - Richard D. Carvajal AU - Elizabeth Philipone AU - Tian Wang AU - Scott M. Peters AU - Claire R. Stewart AU - Fatemeh Momen-Heravi AU - Scott Troob AU - Matt Levin AU - Zohreh AkhavanAghdam AU - Austin J. Shackelford AU - Carleigh R. Canterbury AU - Masataka Shimonosono AU - Hiroshi Nakagawa TI - MicroRNA-based cancer mortality risk scoring system and hTERT expression linked with risk-adjusted treatment strategy in early-stage oral squamous cell carcinoma AID - 10.1101/2020.07.03.20145854 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.03.20145854 4099 - http://medrxiv.org/content/early/2020/07/04/2020.07.03.20145854.short 4100 - http://medrxiv.org/content/early/2020/07/04/2020.07.03.20145854.full AB - We have developed and validated a novel microRNA (miRNA)-based prognostic model to predict survival outcome in oral squamous cell carcinoma (OSCC) patients who are already categorized into ‘early-stage’ by the TNM system. A total of 836 early-stage OSCC patients were assigned the mortality risk scores. We evaluated the efficacy of various treatment regimens in terms of survival benefit compared to surgery only in patients stratified into high and low mortality risk categories. Within the high-risk group, surgery with neck dissection significantly improved the 5-year survival to 75% from 46% (p<0.001) with surgery only. A Cox proportional hazard model on time-to-death suggests a hazard ratio of 0.37 comparing surgery with neck dissection to surgery only (95% CI: 0.2-0.6; p=0.0005). For the low-risk group, surgery only without neck dissection is the most beneficial treatment modality, as opposed to the high-risk group, in which surgery with neck dissection significantly improves 5-year survival. Regardless of treatment selected, those with risk score ≥1 may benefit from additional therapy to prevent cancer relapse. Based on functional analysis of the prognostic miRNAs, we identified hTERT (human telomerase reverse transcriptase) as a promising drug target to prevent cancer relapse, thereby improving cancer-free survival. We also established a functional platform for patient-derived organoid-based drug testing in an effort to link prognostic marker-based mortality risk assessment with appropriate risk-adjusted therapy to improve overall survival.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NIH/NIDCR R01DE026801 (A. Yoon), the NIH/NIEHS P30ES009089 and the NIH/NCI P30CA013696 (Columbia University).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was approved by an IRB at Columbia University Irving Medical Center and it has been conducted by the highest principles of human subject welfare.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data provided in this publication will be available from the corresponding author upon request.